SCHEMBL1084872

SCHEMBL1084872

COc1ccccc1-c1nc2ccccc2c(=O)[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GUSB P08236 9/20 0.78
KDM4E B2RXH2 1/20 0.62
HPGD P15428 1/20 0.62
TNKS O95271 3/20 0.62
TNKS2 Q9H2K2 3/20 0.62
PARP1 P09874 2/20 0.62
NPC1 O15118 1/20 0.62
CASP3 P42574 1/20 0.62
RAB9A P51151 1/20 0.62
SENP7 Q9BQF6 1/20 0.62
SENP6 Q9GZR1 1/20 0.62
CYP1A1 P04798 2/20 0.61
CYP1B1 Q16678 2/20 0.61
CYP1A2 P05177 1/20 0.61
C1R P00736 1/20 0.58
PARP2 Q9UGN5 1/20 0.57
ABL1 P00519 1/20 0.56
LCK P06239 1/20 0.56
LYN P07948 1/20 0.56
SRC P12931 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29740691 1.00 GUSB (0.78) GUSBKDM4EHPGDTNKSTNKS2
SCHEMBL16007938 0.88 GUSB (1.00) GUSBKDM4EHPGDTNKSTNKS2
SCHEMBL13599387 0.85 GUSB (0.70) GUSBTNKSTNKS2PARP1NPC1
SCHEMBL13604403 0.85 GUSB (0.69) GUSBKDM4EHPGDTNKSTNKS2
SCHEMBL23743251 0.85 GUSB (0.72) GUSBKDM4ETNKSTNKS2PARP1
SCHEMBL183953 0.85 GUSB (0.59) GUSBTNKSTNKS2PARP1NPC1
SCHEMBL183430 0.85 GUSB (0.59) GUSBTNKSTNKS2PARP1CYP1A1
SCHEMBL7160589 0.85 GUSB (1.00) GUSBKDM4EHPGD
SCHEMBL10205334 0.85 GUSB (0.68) GUSBKDM4EHPGDTNKSTNKS2
SCHEMBL31238756 0.85 GUSB (1.00) GUSBKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0371731-B1 Quinazolinone derivatives SMITH KLINE FRENCH LAB (GB) 1994-04-20 EP claimed
US-5147875-A 2-(SUBSTITUTED PHENYL)-4-OXO-QUINAZOLINES SANSHIN KOGYO KABISHIKI KAISHA (JP) 1992-09-15 US claimed
EP-0371731-A2 Quinazolinone derivatives SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1990-06-06 EP claimed
US-20240027346-A1 DETECTION METHOD THE UNIVERSITY OF QUEENSLAND (AU) 2024-01-25 US disclosed
CN-109879820-B Synthetic method of quinazolinone heterocyclic compound 扬州大学 2022-07-19 CN disclosed
CN-110272392-B Transition metal catalyzed C-H coupling for efficiently preparing 2- (4(3H) -quinazolinone) aryl alkyl acetate derivative 四川大学 2022-07-01 CN disclosed
US-20170073359-A1 Optically-Detectable Enzyme Substrates and Their Method of Use MOLECULAR PROBES, INC. 2017-03-16 US disclosed
US-20160158390-A1 Methods for Tumor Diagnosis and Therapy PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2016-06-09 US disclosed
US-20160139135-A1 Optically-Detectable Enzyme Substrates and Their Method of Use LIFE TECHNOLOGIES CORP (US) 2016-05-19 US disclosed
US-9320815-B2 Compounds and methods for enzyme-mediated tumor imaging and therapy PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2016-04-26 US disclosed
US-8865891-B2 Optically-detectable enzyme substrates and their method of use Life Technologies Corporation (US) 2014-10-21 US disclosed
EP-1784393-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS Vertex Pharmaceuticals Incorporated (US) 2007-05-16 EP disclosed
US-20060173018-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2006-08-03 US disclosed
WO-2006028904-A9 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2006-06-22 WO disclosed
WO-2006028904-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-03-16 WO disclosed
WO-2006012577-A2 QUINAZOLINONE DERIVATIVES USEFUL FOR THE REGULATION OF GLUCOSE HOMEOSTASIS AND FOOD INTAKE BAYER PHARMACEUTICALS CORPORATION (US) 2006-02-02 WO disclosed
WO-2004078733-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-09-16 WO disclosed
EP-0371731-B1 Quinazolinone derivatives SMITH KLINE FRENCH LAB (GB) 1994-04-20 EP disclosed
US-5147875-A 2-(SUBSTITUTED PHENYL)-4-OXO-QUINAZOLINES SANSHIN KOGYO KABISHIKI KAISHA (JP) 1992-09-15 US disclosed
EP-0371731-A2 Quinazolinone derivatives SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1990-06-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240027346-A1 DETECTION METHOD NCS1, NGF, ACHE GUSB 1599/4885KDM4E 3397/4885HPGD 2340/4885
US-20160139135-A1 Optically-Detectable Enzyme Substrates and Their Method of Use MGAM, LCT, GAA GUSB 22/4885KDM4E 3086/4885HPGD 650/4885
US-20170073359-A1 Optically-Detectable Enzyme Substrates and Their Method of Use MGAM, LCT, GAA GUSB 22/4885KDM4E 3086/4885HPGD 650/4885
US-20060173018-A1 Quinazolines useful as modulators of ion channels KCNQ1, KCNQ2, KCNN3 GUSB 3959/4885KDM4E 2570/4885HPGD 893/4885
US-20160158390-A1 Methods for Tumor Diagnosis and Therapy FOLH1, DNPEP, ENPEP GUSB 21/4885KDM4E 4072/4885HPGD 595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.